The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly’s ‌weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing facilities. If finalized, the move could impact telehealth firms that rely on outsourcing facilities to produce these drugs in bulk, while bolstering Novo and Lilly’s efforts against unauthorized versions ​that are eating into sales of their blockbuster treatments. The regulator said on